Association of MASLD Phenotypes With Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors
Rattachement africain : ca, it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Steatotic liver disease is prevalent among people with hepatitis C virus (HCV). The new definition of metabolic dysfunction-associated steatotic liver disease (MASLD) emphasises the metabolic drivers of steatosis and recognises its frequent coexistence with other chronic liver diseases, including HCV. We aimed to evaluate the association of coexisting MASLD and HCV with liver fibrosis. Individuals with HCV who underwent transient elastography (TE) with associated controlled attenuation parameter (CAP) were included from two clinical centres. MASLD and significant liver fibrosis were defined as the presence of steatosis (CAP ≥ 275 dB/m) with at least one cardiometabolic risk factor, and liver stiffness measurement (LSM) ≥ 7.1 kPa measured by TE, respectively. Associated cofactors of significant liver fibrosis were determined using stepwise regression and cross-validation by LASSO models to select confounders. Among 590 participants, 31% were diagnosed with MASLD. The prevalence of significant liver fibrosis was the highest among people with MASLD (58%) followed by HCV-related steatosis (45%) and the non-steatosis group (39%). After adjusting for potential confounders, MASLD was associated with significant liver fibrosis (adjusted odds ratio [aOR] 2.29, 95% confidence interval [CI] 1.07-4.87). Furthermore, specific MASLD phenotypes including diabetes, hypertension and overweight were associated with significant liver fibrosis, with aORs of 4.76 (95% CI 2.16-10.49), 3.44 (95% CI 1.77-6.68) and 2.54 (95% CI 1.27-5.07), respectively. In conclusion, MASLD is associated with liver fibrosis in people with HCV, specifically the diabetes, overweight and hypertensive phenotypes. Beyond pursuing a virological cure, healthcare providers should prioritise managing metabolic conditions, particularly diabetes, hypertension and obesity.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Association of <scp>MASLD</scp> Phenotypes With Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors
- Date Crossref
- 27/01/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
McGill University Division of Experimental Medicine pays non établi dans la noticeUniversité ou école supérieure
-
University of British Columbia Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
McGill University Health Centre pays non établi dans la noticeÉtablissement de santé
-
University of Milan Department of Pathophysiology pays non établi dans la noticeUniversité ou école supérieure
-
Research Institute of the McGill University Health Centre pays non établi dans la noticeOrganisme public
-
Queen's University Public Health Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Ottawa Hospital Division of Infectious Diseases pays non établi dans la noticeÉtablissement de santé
-
Ottawa Hospital Research Institute pays non établi dans la noticeÉtablissement de santé
Division of Experimental Medicine — McGill University, Department of Medicine — University of British Columbia et McGill University Health Centre, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.